The stromal compartments in pancreatic cancer: Are there any therapeutic targets?

Cancer Letters

Volumn 343, Issue 2, 2014, Pages 147-155

  Lunardi, Serena ^a   Muschel, Ruth J ^a   Brunner, Thomas B ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Pancreatic cancer; Pancreatic Stellate Cells; Stroma; Tumour microenvironment

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CYCLOOXYGENASE 2; CYTOKINE; GEMCITABINE; HYALURONIC ACID; HYALURONIDASE; INTEGRIN; IPILIMUMAB; K RAS PROTEIN; NEUROPILIN 1; PF 562271; PIDILIZUMAB; PROTEIN P53; SARIDEGIB; SCLEROPROTEIN; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; DRUG TARGETING; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; INFLAMMATORY CELL; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC STELLATE CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

COX-2; CTLS; CYCLOOXYGENASE-2; CYTOTOXIC T LYMPHOCYTES; DCS; DENDRITIC CELLS; ECM; EGF; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR MATRIX; FAK; FAP-Α; FGF; FIBROBLAST ACTIVATION PROTEIN-Α; FIBROBLAST GROWTH FACTOR; FOCAL ADHESION KINASE; HEPATIC STELLATE CELL; HSCS; IGF-1; INSULIN GROWTH FACTOR-1; MATRIX METALLOPROTEINASES; MDSCS; MMP; MYELOID-DERIVED SUPPRESSOR CELLS; PANCREATIC CANCER; PANCREATIC CANCER CELLS; PANCREATIC DUCTAL ADENOCARCINOMA; PANCREATIC STELLATE CELLS; PCCS; PDAC; PDGF; PLATELET-DERIVED GROWTH FACTOR; PSCS; REGULATORY T CELLS (TREGS); SECRETED PROTEIN ACIDIC AND RICH IN CYSTEINE; SERBIPINE2; SERINE PROTEASE INHIBITOR NEXIN 2; SHH; SONIC HEDGEHOG; SPARC; STROMA; TAMS; TGF-Β; TIMP; TISSUE INHIBITORS OF METALLOPROTEINASES; TISSUE PLASMINOGEN ACTIVATOR; TPA; TRANSFORMING GROWTH FACTOR-Β; TREGS; TUMOUR ASSOCIATED MACROPHAGES; TUMOUR MICROENVIRONMENT; UPA; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF; Α-SMA; Α-SMOOTH MUSCLE ACTIN;

ANTINEOPLASTIC AGENTS; CELL COMPARTMENTATION; DRUG DELIVERY SYSTEMS; HUMANS; PANCREATIC NEOPLASMS; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84891836864     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.09.039     Document Type: Review

References (136)

1. Apte M.V., Park S., Phillips P.A., Santucci N., Goldstein D., Kumar R.K., Ramm G.A., Buchler M., Friess H., McCarroll J.A., Keogh G., Merrett N., Pirola R., Wilson J.S. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 2004, 29:179-187.
2. Apte M.V., Haber P.S., Applegate T.L., Norton I.D., McCaughan G.W., Korsten M.A., Pirola R.C., Wilson J.S. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut 1998, 43:128-133.
3. Erkan M., Michalski C.W., Rieder S., Reiser-Erkan C., Abiatari I., Kolb A., Giese N.A., Esposito I., Friess H., Kleeff J. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 2008, 6:1155-1161.
4. Gress T.M., Muller-Pillasch F., Lerch M.M., Friess H., Buchler M., Adler G. Expression and in situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int. J. Cancer 1995, 62:407-413.
5. Kanno A., Satoh K., Masamune A., Hirota M., Kimura K., Umino J., Hamada S., Satoh A., Egawa S., Motoi F., Unno M., Shimosegawa T. Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. Int. J. Cancer 2008, 122:2707-2718.
6. Sullivan J., Blair L., Alnajar A., Aziz T., Ng C.Y., Chipitsyna G., Gong Q., Witkiewicz A., Weber G.F., Denhardt D.T., Yeo C.J., Arafat H.A. Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery 2009, 146:232-240.
7. Maisonneuve P., Lowenfels A.B. Epidemiology of pancreatic cancer: an update. Dig. Dis. 2010, 28:645-656.
8. Chipitsyna G., Gong Q., Anandanadesan R., Alnajar A., Batra S.K., Wittel U.A., Cullen D.M., Akhter M.P., Denhardt D.T., Yeo C.J., Arafat H.A. Induction of osteopontin expression by nicotine and cigarette smoke in the pancreas and pancreatic ductal adenocarcinoma cells. Int. J. Cancer 2009, 125:276-285.
9. Infante J.R., Matsubayashi H., Sato N., Tonascia J., Klein A.P., Riall T.A., Yeo C., Iacobuzio-Donahue C., Goggins M. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J. Clin. Oncol. 2007, 25:319-325.
10. Mantoni T.S., Schendel R.R., Rodel F., Niedobitek G., Al-Assar O., Masamune A., Brunner T.B. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol. Ther. 2008, 7:1806-1815.
11. Desai N., Trieu V., Damascelli B., Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl. Oncol. 2009, 2:59-64.
12. Von Hoff D.D., Ramanathan R.K., Borad M.J., Laheru D.A., Smith L.S., Wood T.E., Korn R.L., Desai N., Trieu V., Iglesias J.L., Zhang H., Soon-Shiong P., Shi T., Rajeshkumar N.V., Maitra A., Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 2011, 29:4548-4554.
13. Von Hoff D. Final Results of a Randomized Phase III Study of Weekly Nab-paclitaxel Plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas 2013, ASCO, San Francisco CA, USA.
14. Alvarez R., Musteanu M., Garcia-Garcia E., Lopez-Casas P.P., Megias D., Guerra C., Munoz M., Quijano Y., Cubillo A., Rodriguez-Pascual J., Plaza C., de Vicente E., Prados S., Tabernero S., Barbacid M., Lopez-Rios F., Hidalgo M. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br. J. Cancer 2013.
15. Lee H.O., Mullins S.R., Franco-Barraza J., Valianou M., Cukierman E., Cheng J.D. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 2011, 11:245.
16. Crnogorac-Jurcevic T., Efthimiou E., Capelli P., Blaveri E., Baron A., Terris B., Jones M., Tyson K., Bassi C., Scarpa A., Lemoine N.R. Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 2001, 20:7437-7446.
17. Farrow B., Berger D.H., Rowley D. Tumor-derived pancreatic stellate cells promote pancreatic cancer cell invasion through release of thrombospondin-2. J. Surg. Res. 2009, 156:155-160.
18. Yoshida S., Yokota T., Ujiki M., Ding X.Z., Pelham C., Adrian T.E., Talamonti M.S., Bell R.H., Denham W. Pancreatic cancer stimulates pancreatic stellate cell proliferation and TIMP-1 production through the MAP kinase pathway. Biochem. Biophys. Res. Commun. 2004, 323:1241-1245.
19. Maatta M., Soini Y., Liakka A., Autio-Harmainen H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin. Cancer Res. 2000, 6:2726-2734.
20. Qian X., Rothman V.L., Nicosia R.F., Tuszynski G.P. Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production. Pathol. Oncol. Res. 2001, 7:251-259.
21. Paron I., Berchtold S., Voros J., Shamarla M., Erkan M., Hofler H., Esposito I. Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway. PLoS One 2011, 6:e21684.
22. Gorantla B., Asuthkar S., Rao J.S., Patel J., Gondi C.S. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells. Mol. Cancer Res. 2011, 9:377-389.
23. Roda O., Ortiz-Zapater E., Martinez-Bosch N., Gutierrez-Gallego R., Vila-Perello M., Ampurdanes C., Gabius H.J., Andre S., Andreu D., Real F.X., Navarro P. Galectin-1 is a novel functional receptor for tissue plasminogen activator in pancreatic cancer. Gastroenterology 2009, 136(1379-90):e1-e5.
24. Mahadevan D., Von Hoff D.D. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol. Cancer Ther. 2007, 6:1186-1197.
25. Ohlund D., Franklin O., Lundberg E., Lundin C., Sund M. Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop. BMC Cancer 2013, 13:154.
26. Shields M.A., Dangi-Garimella S., Krantz S.B., Bentrem D.J., Munshi H.G. Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. J. Biol. Chem. 2011, 286:10495-10504.
27. Miyamoto H., Murakami T., Tsuchida K., Sugino H., Miyake H., Tashiro S. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 2004, 28:38-44.
28. Provenzano P.P., Cuevas C., Chang A.E., Goel V.K., Von Hoff D.D., Hingorani S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:418-429.
29. Jacobetz M.A., Chan D.S., Neesse A., Bapiro T.E., Cook N., Frese K.K., Feig C., Nakagawa T., Caldwell M.E., Zecchini H.I., Lolkema M.P., Jiang P., Kultti A., Thompson C.B., Maneval D.C., Jodrell D.I., Frost G.I., Shepard H.M., Skepper J.N., Tuveson D.A. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2012.
30. Clark C.E., Hingorani S.R., Mick R., Combs C., Tuveson D.A., Vonderheide R.H. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007, 67:9518-9527.
31. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4:71-78.
32. Bronte V., Serafini P., Mazzoni A., Segal D.M., Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 2003, 24:302-306.
33. Hao N.B., Lu M.H., Fan Y.H., Cao Y.L., Zhang Z.R., Yang S.M. Macrophages in tumor microenvironments and the progression of tumors. Clin. Dev. Immunol. 2012, 2012:948098.
34. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
35. Mitchem J.B., Brennan D.J., Knolhoff B.L., Belt B.A., Zhu Y., Sanford D.E., Belaygorod L., Carpenter D., Collins L., Piwnica-Worms D., Hewitt S., Udupi G.M., Gallagher W.M., Wegner C., West B.L., Wang-Gillam A., Goedegebuure P., Linehan D.C., DeNardo D.G. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013, 73:1128-1141.
36. Bronte V., Wang M., Overwijk W.W., Surman D.R., Pericle F., Rosenberg S.A., Restifo N.P. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J. Immunol. 1998, 161:5313-5320.
37. Kusmartsev S.A., Li Y., Chen S.H. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J. Immunol. 2000, 165:779-785.
38. Gabrilovich D.I., Velders M.P., Sotomayor E.M., Kast W.M. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol. 2001, 166:5398-5406.
39. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., Divino C.M., Chen S.H. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell energy in tumor-bearing host. Cancer Res. 2006, 66:1123-1131.
40. Pylayeva-Gupta Y., Lee K.E., Hajdu C.H., Miller G., Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 2012, 21:836-847.
41. Bayne L.J., Beatty G.L., Jhala N., Clark C.E., Rhim A.D., Stanger B.Z., Vonderheide R.H. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012, 21:822-835.
42. Kubuschok B., Xie X., Jesnowski R., Preuss K.D., Romeike B.F., Neumann F., Regitz E., Pistorius G., Schilling M., Scheunemann P., Izbicki J.R., Lohr J.M., Pfreundschuh M. Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis. Int. J. Cancer 2004, 109:568-575.
43. Schmitz-Winnenthal F.H., Volk C., Z'Graggen K., Galindo L., Nummer D., Ziouta Y., Bucur M., Weitz J., Schirrmacher V., Buchler M.W., Beckhove P. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res. 2005, 65:10079-10087.
44. Ryschich E., Notzel T., Hinz U., Autschbach F., Ferguson J., Simon I., Weitz J., Frohlich B., Klar E., Buchler M.W., Schmidt J. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin. Cancer Res. 2005, 11:498-504.
45. Fukunaga A., Miyamoto M., Cho Y., Murakami S., Kawarada Y., Oshikiri T., Kato K., Kurokawa T., Suzuoki M., Nakakubo Y., Hiraoka K., Itoh T., Morikawa T., Okushiba S., Kondo S., Katoh H. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 2004, 28:e26-e31.
46. von Bernstorff W., Voss M., Freichel S., Schmid A., Vogel I., Johnk C., Henne-Bruns D., Kremer B., Kalthoff H. Systemic and local immunosuppression in pancreatic cancer patients. Clin. Cancer Res. 2001, 7:925s-932s.
47. von Bernstorff W., Spanjaard R.A., Chan A.K., Lockhart D.C., Sadanaga N., Wood I., Peiper M., Goedegebuure P.S., Eberlein T.J. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 1999, 125:73-84.
48. Hiraoka N., Onozato K., Kosuge T., Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 2006, 12:5423-5434.
49. Liyanage U.K., Moore T.T., Joo H.G., Tanaka Y., Herrmann V., Doherty G., Drebin J.A., Strasberg S.M., Eberlein T.J., Goedegebuure P.S., Linehan D.C. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 2002, 169:2756-2761.
50. Vizio B., Novarino A., Giacobino A., Cristiano C., Prati A., Ciuffreda L., Montrucchio G., Bellone G. Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome. Exp. Ther. Med. 2012, 4:70-78.
51. Wing K., Fehervari Z., Sakaguchi S. Emerging possibilities in the development and function of regulatory T cells. Int. Immunol. 2006, 18:991-1000.
52. Zou W., Regulatory T. Cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 2006, 6:295-307.
53. Dodson L.F., Hawkins W.G., Goedegebuure P. Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy 2011, 3:517-537.
54. Jaffee E.M., Hruban R.H., Biedrzycki B., Laheru D., Schepers K., Sauter P.R., Goemann M., Coleman J., Grochow L., Donehower R.C., Lillemoe K.D., O'Reilly S., Abrams R.A., Pardoll D.M., Cameron J.L., Yeo C.J. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 2001, 19:145-156.
55. Vanneman M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 2012, 12:237-251.
56. Royal R.E., Levy C., Turner K., Mathur A., Hughes M., Kammula U.S., Sherry R.M., Topalian S.L., Yang J.C., Lowy I., Rosenberg S.A. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 2010, 33:828-833.
57. Buchler P., Reber H.A., Lavey R.S., Tomlinson J., Buchler M.W., Friess H., Hines O.J. Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. J. Surg. Res. 2004, 120:295-303.
58. Koong A.C., Mehta V.K., Le Q.T., Fisher G.A., Terris D.J., Brown J.M., Bastidas A.J., Vierra M. Pancreatic tumors show high levels of hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48:919-922.
59. Schwartz D.L., Bankson J.A., Lemos R., Lai S.Y., Thittai A.K., He Y., Hostetter G., Demeure M.J., Von Hoff D.D., Powis G. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol. Cancer Ther. 2010, 9:2057-2067.
60. Esposito I., Kayed H., Keleg S., Giese T., Sage E.H., Schirmacher P., Friess H., Kleeff J. Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia 2007, 9:8-17.
61. Hlatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and does not tell us. J. Natl. Cancer Inst. 2002, 94:883-893.
62. Seo Y., Baba H., Fukuda T., Takashima M., Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000, 88:2239-2245.
63. Buchler P., Reber H.A., Buchler M.W., Friess H., Hines O.J. VEGF-RII influences the prognosis of pancreatic cancer. Ann. Surg. 2002, 236:738-749. (discussion 49).
64. Wang H.X., Chen Q.K. Expression and significance of cyclooxygenase-2 in human pancreatic carcinomas. Ai Zheng 2003, 22:649-652.
65. Fukahi K., Fukasawa M., Neufeld G., Itakura J., Korc M. Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells. Clin. Cancer Res. 2004, 10:581-590.
66. Kindler H.L., Niedzwiecki D., Hollis D., Sutherland S., Schrag D., Hurwitz H., Innocenti F., Mulcahy M.F., O'Reilly E., Wozniak T.F., Picus J., Bhargava P., Mayer R.J., Schilsky R.L., Goldberg R.M. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 2010, 28:3617-3622.
67. Mizukami Y., Jo W.S., Duerr E.M., Gala M., Li J., Zhang X., Zimmer M.A., Iliopoulos O., Zukerberg L.R., Kohgo Y., Lynch M.P., Rueda B.R., Chung D.C. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat. Med. 2005, 11:992-997.
68. Ijichi H. Inhibition of CXCLs/CXCR2 axis in the tumor microenvironment might be a potent therapeutics for pancreatic cancer. Oncolmmunology 2012, 1:569-571.
69. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., Frese K.K., Denicola G., Feig C., Combs C., Winter S.P., Ireland-Zecchini H., Reichelt S., Howat W.J., Chang A., Dhara M., Wang L., Ruckert F., Grutzmann R., Pilarsky C., Izeradjene K., Hingorani S.R., Huang P., Davies S.E., Plunkett W., Egorin M., Hruban R.H., Whitebread N., McGovern K., Adams J., Iacobuzio-Donahue C., Griffiths J., Tuveson D.A. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
70. InfinityPharmaceuticals. <> (accessed 09.08.13). http://phx.corporate-ir.net/phoenix.zhtml?c=121941&p=irol-newsArticle&ID=1653550&highlight=.
71. Yamazaki M., Nakamura K., Mizukami Y., Ii M., Sasajima J., Sugiyama Y., Nishikawa T., Nakano Y., Yanagawa N., Sato K., Maemoto A., Tanno S., Okumura T., Karasaki H., Kono T., Fujiya M., Ashida T., Chung D.C., Kohgo Y. Sonic hedgehog derived from human pancreatic cancer cells augments angiogenic function of endothelial progenitor cells. Cancer Sci. 2008, 99:1131-1138.
72. Renault M.A., Roncalli J., Tongers J., Thorne T., Klyachko E., Misener S., Volpert O.V., Mehta S., Burg A., Luedemann C., Qin G., Kishore R., Losordo D.W. Sonic hedgehog induces angiogenesis via Rho kinase-dependent signaling in endothelial cells. J. Mol. Cell. Cardiol. 2010, 49:490-498.
73. Pola R., Ling L.E., Silver M., Corbley M.J., Kearney M., Blake Pepinsky R., Shapiro R., Taylor F.R., Baker D.P., Asahara T., Isner J.M. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat. Med. 2001, 7:706-711.
74. Kloppel G., Detlefsen S., Feyerabend B. Fibrosis of the pancreas: the initial tissue damage and the resulting pattern. Virchows Arch. 2004, 445:1-8.
75. Brentnall T.A., Lai L.A., Coleman J., Bronner M.P., Pan S., Chen R. Arousal of cancer-associated stroma: overexpression of paladin activates fibroblasts to promote tumor invasion. PLoS One 2012, 7:e30219.
76. Direkze N.C., Hodivala-Dilke K., Jeffery R., Hunt T., Poulsom R., Oukrif D., Alison M.R., Wright N.A. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 2004, 64:8492-8495.
77. Lamagna C., Bergers G. The bone marrow constitutes a reservoir of pericyte progenitors. J. Leukocyte Biol. 2006, 80:677-681.
78. Song S., Ewald A.J., Stallcup W., Werb Z., Bergers G. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat. Cell Biol. 2005, 7:870-879.
79. Iacobuzio-Donahue C.A., Ryu B., Hruban R.H., Kern S.E. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am. J. Pathol. 2002, 160:91-99.
80. Sugimoto H., Mundel T.M., Kieran M.W., Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol. Ther. 2006, 5:1640-1646.
81. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
82. Ishii G., Sangai T., Oda T., Aoyagi Y., Hasebe T., Kanomata N., Endoh Y., Okumura C., Okuhara Y., Magae J., Emura M., Ochiya T., Ochiai A. Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem. Biophys. Res. Commun. 2003, 309:232-240.
83. Direkze N.C., Jeffery R., Hodivala-Dilke K., Hunt T., Playford R.J., Elia G., Poulsom R., Wright N.A., Alison M.R. Bone marrow-derived stromal cells express lineage-related messenger RNA species. Cancer Res. 2006, 66:1265-1269.
84. Apte M.V., Haber P.S., Darby S.J., Rodgers S.C., McCaughan G.W., Korsten M.A., Pirola R.C., Wilson J.S. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut 1999, 44:534-541.
85. Bachem M.G., Schneider E., Gross H., Weidenbach H., Schmid R.M., Menke A., Siech M., Beger H., Grunert A., Adler G. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 1998, 115:421-432.
86. Bachem M.G., Schunemann M., Ramadani M., Siech M., Beger H., Buck A., Zhou S., Schmid-Kotsas A., Adler G. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 2005, 128:907-921.
87. Apte M.V., Phillips P.A., Fahmy R.G., Darby S.J., Rodgers S.C., McCaughan G.W., Korsten M.A., Pirola R.C., Naidoo D., Wilson J.S. Does alcohol directly stimulate pancreatic fibrogenesis? Studies with rat pancreatic stellate cells. Gastroenterology 2000, 118:780-794.
88. Watanabe S., Nagashio Y., Asaumi H., Nomiyama Y., Taguchi M., Tashiro M., Kihara Y., Nakamura H., Otsuki M. Pressure activates rat pancreatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287:G1175-G1181.
89. Asaumi H., Watanabe S., Taguchi M., Tashiro M., Otsuki M. Externally applied pressure activates pancreatic stellate cells through the generation of intracellular reactive oxygen species. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293:G972-G978.
90. Apte M.V., Pirola R.C., Wilson J.S. Battle-scarred pancreas: role of alcohol and pancreatic stellate cells in pancreatic fibrosis. J. Gastroenterol. Hepatol. 2006, 21(Suppl. 3):S97-S101.
91. Omary M.B., Lugea A., Lowe A.W., Pandol S.J. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J. Clin. Invest. 2007, 117:50-59.
92. Lohr M., Schmidt C., Ringel J., Kluth M., Muller P., Nizze H., Jesnowski R. Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 2001, 61:550-555.
93. Yoshida S., Ujiki M., Ding X.Z., Pelham C., Talamonti M.S., Bell R.H., Denham W., Adrian T.E. Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs. Mol. Cancer 2005, 4:27.
94. Bailey J.M., Swanson B.J., Hamada T., Eggers J.P., Singh P.K., Caffery T., Ouellette M.M., Hollingsworth M.A. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin. Cancer Res. 2008, 14:5995-6004.
95. Erkan M., Kleeff J., Gorbachevski A., Reiser C., Mitkus T., Esposito I., Giese T., Buchler M.W., Giese N.A., Friess H. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 2007, 132:1447-1464.
96. Fujita H., Ohuchida K., Mizumoto K., Egami T., Miyoshi K., Moriyama T., Cui L., Yu J., Zhao M., Manabe T., Tanaka M. Tumor-stromal interactions with direct cell contacts enhance proliferation of human pancreatic carcinoma cells. Cancer Sci. 2009.
97. Hwang R.F., Moore T., Arumugam T., Ramachandran V., Amos K.D., Rivera A., Ji B., Evans D.B., Logsdon C.D. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008, 68:918-926.
98. Jiang H.B., Xu M., Wang X.P. Pancreatic stellate cells promote proliferation and invasiveness of human pancreatic cancer cells via galectin-3. World J. Gastroenterol. 2008, 14:2023-2028.
99. Vonlaufen A., Joshi S., Qu C., Phillips P.A., Xu Z., Parker N.R., Toi C.S., Pirola R.C., Wilson J.S., Goldstein D., Apte M.V. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 2008, 68:2085-2093.
100. Vaquero E.C., Edderkaoui M., Nam K.J., Gukovsky I., Pandol S.J., Gukovskaya A.S. Extracellular matrix proteins protect pancreatic cancer cells from death via mitochondrial and nonmitochondrial pathways. Gastroenterology 2003, 125:1188-1202.
101. Froeling F.E., Feig C., Chelala C., Dobson R., Mein C.E., Tuveson D.A., Clevers H., Hart I.R., Kocher H.M. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-beta-catenin signaling to slow tumor progression. Gastroenterology 2011, 141:1486-1497. 97 e1-14.
102. Schneiderhan W., Diaz F., Fundel M., Zhou S., Siech M., Hasel C., Moller P., Gschwend J.E., Seufferlein T., Gress T., Adler G., Bachem M.G. Pancreatic stellate cells are an important source of MMP-2 in human pancreatic cancer and accelerate tumor progression in a murine xenograft model and CAM assay. J. Cell Sci. 2007, 120:512-519.
103. Neesse A., Wagner M., Ellenrieder V., Bachem M., Gress T.M., Buchholz M. Pancreatic stellate cells potentiate proinvasive effects of SERPINE2 expression in pancreatic cancer xenograft tumors. Pancreatology 2007, 7:380-385.
104. Buchholz M., Biebl A., Neesse A., Wagner M., Iwamura T., Leder G., Adler G., Gress T.M. SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. Cancer Res. 2003, 63:4945-4951.
105. Ikenaga N., Ohuchida K., Mizumoto K., Cui L., Kayashima T., Morimatsu K., Moriyama T., Nakata K., Fujita H., Tanaka M. CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer. Gastroenterology 2010, 139:1041-1051. 51 e1-8.
106. Xu Z., Vonlaufen A., Phillips P.A., Fiala-Beer E., Zhang X., Yang L., Biankin A.V., Goldstein D., Pirola R.C., Wilson J.S., Apte M.V. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am. J. Pathol. 2010, 177:2585-2596.
107. Erkan M., Reiser-Erkan C., Michalski C.W., Deucker S., Sauliunaite D., Streit S., Esposito I., Friess H., Kleeff J. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia 2009, 11:497-508.
108. Masamune A., Kikuta K., Watanabe T., Satoh K., Hirota M., Shimosegawa T. Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295:G709-G717.
109. Winau F., Quack C., Darmoise A., Kaufmann S.H. Starring stellate cells in liver immunology. Curr. Opin. Immunol. 2008, 20:68-74.
110. Masamune A., Kikuta K., Watanabe T., Satoh K., Satoh A., Shimosegawa T. Pancreatic stellate cells express Toll-like receptors. J. Gastroenterol. 2008, 43:352-362.
111. Shimizu K., Hashimoto K., Tahara J., Imaeda H., Andoh A., Shiratori K. Pancreatic stellate cells do not exhibit features of antigen-presenting cells. Pancreas 2012, 41:422-427.
112. Mace T.A., Ameen Z., Collins A., Wojcik S., Mair M., Young G.S., Fuchs J.R., Eubank T.D., Frankel W.L., Bekaii-Saab T., Bloomston M., Lesinski G.B. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res. 2013.
113. Ene-Obong A., Clear A.J., Watt J., Wang J., Fatah R., Riches J.C., Marshall J.F., Chin-Aleong J., Chelala C., Gribben J.G., Ramsay A.G., Kocher H.M. Activated pancreatic stellate cells sequester CD8+ T-cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology 2013.
114. Kraman M., Bambrough P.J., Arnold J.N., Roberts E.W., Magiera L., Jones J.O., Gopinathan A., Tuveson D.A., Fearon D.T. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010, 330:827-830.
115. Muerkoster S., Wegehenkel K., Arlt A., Witt M., Sipos B., Kruse M.L., Sebens T., Kloppel G., Kalthoff H., Folsch U.R., Schafer H. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res. 2004, 64:1331-1337.
116. Muerkoster S.S., Werbing V., Koch D., Sipos B., Ammerpohl O., Kalthoff H., Tsao M.S., Folsch U.R., Schafer H. Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma-epigenetic downregulation of caspases. Int. J. Cancer 2008, 123:1751-1760.
117. Mantoni T.S., Lunardi S., Al-Assar O., Masamune A., Brunner T.B. Pancreatic stellate cells radioprotect pancreatic cancer cells through beta1-integrin signaling. Cancer Res. 2011, 71:3453-3458.
118. Park C.C., Zhang H.J., Yao E.S., Park C.J., Bissell M.J. Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res. 2008, 68:4398-4405.
119. Eke I., Koch U., Hehlgans S., Sandfort V., Stanchi F., Zips D., Baumann M., Shevchenko A., Pilarsky C., Haase M., Baretton G.B., Calleja V., Larijani B., Fassler R., Cordes N. PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. J. Clin. Invest. 2010, 120:2516-2527.
120. Estrugo D., Fischer A., Hess F., Scherthan H., Belka C., Cordes N. Ligand bound beta1 integrins inhibit procaspase-8 for mediating cell adhesion-mediated drug and radiation resistance in human leukemia cells. PLoS One 2007, 2:e269.
121. Stokes J.B., Adair S.J., Slack-Davis J.K., Walters D.M., Tilghman R.W., Hershey E.D., Lowrey B., Thomas K.S., Bouton A.H., Hwang R.F., Stelow E.B., Parsons J.T., Bauer T.W. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol. Cancer Ther. 2011, 10:2135-2145.
122. Burris H., Storniolo A.M. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur. J. Cancer 1997, 33(Suppl. 1):S18-S22.
123. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardiere C., Bennouna J., Bachet J.B., Khemissa-Akouz F., Pere-Verge D., Delbaldo C., Assenat E., Chauffert B., Michel P., Montoto-Grillot C., Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364:1817-1825.
124. Mahlbacher V., Sewing A., Elsasser H.P., Kern H.F. Hyaluronan is a secretory product of human pancreatic adenocarcinoma cells. Eur. J Cell Biol. 1992, 58:28-34.
125. Fries H., Elsasser H.P., Mahlbacher V., Neumann K., Kern H.F. Localisation of hyaluronate (HA) in primary tumors and nude mouse xenografts of human pancreatic carcinomas using a biotinylated HA-binding protein. Virchows Arch. 1994, 424:7-12.
126. Jaskiewicz K., Nalecz A., Rzepko R., Sledzinski Z. Immunocytes and activated stellate cells in pancreatic fibrogenesis. Pancreas 2003, 26:239-242.
127. Primo L., Seano G., Roca C., Maione F., Gagliardi P.A., Sessa R., Martinelli M., Giraudo E., di Blasio L., Bussolino F. Increased expression of alpha6 integrin in endothelial cells unveils a proangiogenic role for basement membrane. Cancer Res. 2010, 70:5759-5769.
128. Naito Z. Role of the small leucine-rich proteoglycan (SLRP) family in pathological lesions and cancer cell growth. J Nihon Med. Sch. 2005, 72:137-145.
129. Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen-Ong G.L., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M., Hruban R.H. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 2003, 63:8614-8622.
130. Shek F.W., Benyon R.C., Walker F.M., McCrudden P.R., Pender S.L., Williams E.J., Johnson P.A., Johnson C.D., Bateman A.C., Fine D.R., Iredale J.P. Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis. Am. J. Pathol. 2002, 160:1787-1798.
131. Baril P., Gangeswaran R., Mahon P.C., Caulee K., Kocher H.M., Harada T., Zhu M., Kalthoff H., Crnogorac-Jurcevic T., Lemoine N.R. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene 2007, 26:2082-2094.
132. Shimoyama S., Gansauge F., Gansauge S., Oohara T., Beger H.G. Altered expression of extracellular matrix molecules and their receptors in chronic pancreatitis and pancreatic adenocarcinoma in comparison with normal pancreas. Int. J. Pancreatol. 1995, 18:227-234.
133. Esposito I., Penzel R., Chaib-Harrireche M., Barcena U., Bergmann F., Riedl S., Kayed H., Giese N., Kleeff J., Friess H., Schirmacher P. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J. Pathol. 2006, 208:673-685.
134. Mauri P., Scarpa A., Nascimbeni A.C., Benazzi L., Parmagnani E., Mafficini A., Della Peruta M., Bassi C., Miyazaki K., Sorio C. Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. FASEB J. 2005, 19:1125-1127.
135. Linder S., Castanos-Velez E., von Rosen A., Biberfeld P. Immunohistochemical expression of extracellular matrix proteins and adhesion molecules in pancreatic carcinoma. Hepatogastroenterology 2001, 48:1321-1327.
136. Bauer J.S., Schreiner C.L., Giancotti F.G., Ruoslahti E., Juliano R.L. Motility of fibronectin receptor-deficient cells on fibronectin and vitronectin: collaborative interactions among integrins. J Cell Biol. 1992, 116:477-487.